Silence Therapeutics plc Current Financial Assets At Amortised Cost
Silence Therapeutics plc (SLN) had Current Financial Assets At Amortised Cost of GBP 16.33 million as of 2022-12-31, per its 20-F filed 2024-03-13.
Discontinued › Notes
ifrs-full:CurrentFinancialAssetsAtAmortisedCost · last filed 2024-03-13
- 2022-12-31: Current Financial Assets At Amortised Cost 16.33M GBP.
- 2020-12-31: Current Financial Assets At Amortised Cost 10.00M GBP.
- 2019-12-31: Current Financial Assets At Amortised Cost 20.00M GBP.
- 2018-12-31: Current Financial Assets At Amortised Cost 5.04M GBP.
| Period end | Current Financial Assets At Amortised Cost |
|---|---|
| 2022-12-31 | 16.33M GBP 20-F · filed 2024-03-13 |
| 2020-12-31 | 10.00M GBP 20-F/A · filed 2021-04-29 |
| 2019-12-31 | 20.00M GBP 20-F/A · filed 2021-04-29 |
| 2018-12-31 | 5.04M GBP 20-F/A · filed 2021-04-29 |